Evgen Pharma Investors - EVG

Evgen Pharma Investors - EVG

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type
Evgen Pharma Plc EVG London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 5.65 08:00:20
Open Price Low Price High Price Close Price Previous Close
5.65 5.65 5.65 5.65 5.65
more quote information »
Industry Sector

Top Investor Posts

amaretto1: Like many on Advfn ... u really don't understand or know what's going on.Many of you will not have traded a bear market yet !!Listen to seasoned investors, if they have seen a bear market,., they are pretty good !
lovewinshatelosses: I think we will start to get some new investors here from next week, as today's news gets digested in the days (and the weekend) ahead. That said, over 17m traded so far cannot just be existing II's and PI's, including Kight's 1m, so maybe traders? Either way, I am struggling to see the appeal of selling any stock right now, even allowing for a retrace at some point. Even if I had a 5p average and was only in for a quick trade, I would be looking for at least 10p to that end, but each to their own of course.
lovewinshatelosses: I would go even further and suggest that this would fly, in the event of some heavy inside buying, On Target. I cannot be the only PI here who would have bought a lot more stock during that raise, if it had seen at least some of the Directors join the party. It would also encourage some new investors, I suspect. Anyway, at least we are not getting hammered in this new phase of stock market panic (apologies if I have now jinxed it and we do join the sell off!).
on target: Director buys preferably tburns. The low director participation here (including the £300-worth or whatever it was one of them got in the placing) is one of the main points for bears here, and irritating for most investors too I'm sure.
amaretto1: That's your opinion ! Any one taking a 5 percent stake in any company, i can assure you is not in for the short term trade...He's odviously privy to the huge potencial, I'm not happy with the share price at all, but it does give private investors the same opportunity price wise...For those that are just taking a position ....Sadly I'm not one of them, my position has now a avg of 10 pence !!
diamondstar1: Despite some of my negativity with regards to the STAR Trial, I believe that ex-CEO Stephen Franklin’s initiative to get the trial started with Prof. Chalmers was simply BRILLIANT. Why? Because so much free money was available for COVID research, it was simply another opportunity to raise the profile of Evgen. This has allowed Evgen to raise a further round of funding at a higher share price, and attract institutional investors. Without the STAR Trial and interest in COVID - my feeling is that share price would dropped further - and they would have had to raise funding at much lower valuations. So, at least current share price is underpinned by cash in hand circa £10 million. But think about this guys - why have they now failed on 2 occasions in getting a positive trial result ie for SAH and now ARDS? They are not selecting their disease targets properly! Why is US-based Reata Pharmaceuticals - founded in 2002 (with their lead product Bardoloxone - a NRF2 upregulator) - worth $5 billion in market cap? Why is Evgen Pharma - founded in 2007 - with NRF2 activator SFX-01 - only valued at £13 million?
amaretto1: They are shafting small cap accross the board... pulling out leaving the private investors holding the baby !!Any rise will be sold in toThis is holding up better than most.Your dealing with crooks who will use paid ramping gangs and journos It's blatantly odvious what they are doing..Many private investors will lose all, esp the spread bet gang.It's not a new process ... this is the shark pit of money managers.Walbrook PR seem to be on many of the spikes and dump tickers !!
moneymunch: " Two of the most recent examples are the placings by Evgen Pharma plc, the clinical stage company focussed on the treatment of cancer and inflammation, and Synairgen plc, the respiratory drug discovery and development company, both listed on AIM. These biotechs are suddenly in the enviable position of having to choose between scaling back allocations or only accepting the money on the table from specific investors." ......................... Booming biotech sector allows for choices over investment Out-Law Analysis | 23 Feb 2021 There has been a growing interest in biotech companies since the onset of the Covid-19 pandemic. Over $13 billion was invested worldwide in biotech companies in 2020 alone. As a result of this increased flow of capital into the sector, biotech companies are becoming more selective about the investors with whom they choose to partner, taking a longer term view than might have previously been the case in a sector in which the cash burn rate from R&D is well known. This theme of the discerning biotech was a central focus at the recent LSX World Congress. This annual event brings together life sciences industry executives – from those involved in start-ups to those leading the world's biggest pharmaceutical companies – and the investment community. Investors without any particular insights into the sector are naturally drawn to the human stories behind products, and in the biotech sector there is no shortage of narrative that companies can play on Widening interest in the sector Specialist healthcare investors know that investment in biotechs requires a long-term view, recognising that it can take years of research and substantial capital for companies to develop new products and deliver meaningful returns on their investment. The risk involved in picking the correct companies to invest in, and at the right time, has meant that the sector has been the domain of specialist investors who understand the science. This changed with the onset of the pandemic when a growing number of investors recognised that, with so many biotechs pivoting ongoing trials to test whether existing products in development had application to coronavirus, any good news from those companies could lead to substantial bumps in share prices, often in excess of 100%. The potential size of these returns suddenly outweighed the risk that had previously made non-specialist healthcare investors wary of the sector. Moreover, driven by the turmoil in sectors such as retail, hospitality and airlines, companies in the life sciences sector felt like a relatively safe place for institutions to invest. A McKinsey study highlighted at the LSX World Congress indicated that, while biotechs listed on the public markets did experience a downturn in share prices in spring 2020, that downturn was short-lived, with average share prices rising 39% in Europe, 37% in the US and 106% in China between 1 January 2020 and 19 January 2021. As a result, much of the recent investment interest in the biotech sector has been from non-specialist investors whose attention has been drawn by the sector's resilience to the Covid-19 pandemic. Industry success stories also help to raise the profile of the sector. The rise to international prominence of German biotech BioNTech, following its partnership with Pfizer and development of a Covid-19 vaccine, is an example of the attention the sector is gaining for its innovation and real-life impact. Investors without any particular insights into the sector are also naturally drawn to the human stories behind products, and in the biotech sector there is no shortage of narrative that companies can play on. For instance, with recent advances in the use of data and technology, companies have been able to focus their innovation around a 'patient-centric' approach to medicine, with personalised medicine, including cell and gene therapies, which show such promise in the treatment of rare diseases, coming to prominence. Increasingly, the 'story' behind, or theoretic potential of, a product is more important than the data behind it, particularly for non-specialist healthcare investors. This growing interest in the sector has resulted in many of the equity fundraisings conducted by publicly traded biotechs being significantly over-subscribed, as more investors have sought to put their faith in biotech stocks. Two of the most recent examples are the placings by Evgen Pharma plc, the clinical stage company focussed on the treatment of cancer and inflammation, and Synairgen plc, the respiratory drug discovery and development company, both listed on AIM. These biotechs are suddenly in the enviable position of having to choose between scaling back allocations or only accepting the money on the table from specific investors. In addition, the increased flow of cash into the sector is prompting competition between investors about the timing of their investment, with an increasing number prepared to invest earlier in the life cycle of a biotech, often at the 'Series A' funding round. Certain funds that traditionally have been focussed on public markets are re-assessing this focus and looking more closely at early stage biotechs. Marshall Wace and Third Point are two big hedge funds that are currently raising money – $400m and $300m, respectively – to invest in privately held healthcare companies that are between six months and two years out from IPO, with a view to holding on to those companies after they list. While the recent returns on many investments in listed biotechs is impressive, some investors are recognising that even they can be dwarfed if they give their backing to the right company early enough in its development. Those investors know that the best value will come from investing early in a company at cheaper valuations, with the rewards coming if that company has a product approved. The risk/reward analysis has been tipped in favour of reward by the evident strength of biotechs over the last 12 months. hTtps://www.pinsentmasons.com/out-law/analysis/booming-biotech-sector-allows-for-choices-over-investment
timbo003: >>>MM You state "SFX-01's recruitment unlike the stop Covid trial, is from patients displaying symptoms of Ards and pneumnonia, regardless of testing positive and/or regardless of being hospitalised" That is incorrect: All patients recruited to the study will be hospitalised. >>>boker All we know about timings is what the company has told us, i.e. data from the STAR COVID study could be potentially available in Q4 2021. I have no reason to doubt that. Have you? It seems to me that you are implying that the company are misleading investors by failing to state that the data will be available earlier (in Q3 or even Q2?). I do not know how many sites are involved in this early stage of the study, (and nor do any of the other contributers to this thread), although I suspect the number of sites involved at this stage it is one or two (based on my own experience in Clinical trials), but whatever the number, the only hard information we have is that they recruited 9 patients within a period of about two weeks. As for extrapolating recruitment data, if they continue to recruit approximately 20 patients/month, a straight line extrapolation takes them to May for completing the first 100 patients and June for the BSDM review , the most logical time to ramp up the number of study sites would be in June (assuming the DSDM review gives the green light for futility and safety). This should then lead to a significant increase in recruitment rate and lead up to a reporting date which was entirely consistant with the company's own estimates of Q4. As for my views on the timings of a BSDM review, we have no definitive information and it will depend on numerous fators, but any time between April and June seems like a reasonable assumption to me. Anyway, this is now getting repetitive (and of little interest to most investors/potential investors) and the timings will have little consequence on what really matters and that is the outcome of the STAR-COVID study. I have let this debate run (despite the repetition) over the last few days as the markets have been closed. I now propose to let you and MM have the last word on this and thereafter unless there is new information available on the topic, I will exercise my moderators discretion on repetitive posts made by any black posters.
timbo003: >>>On Target, Thanks for that, so LifeArc (the paymasters) state up to 6 sites, which suggests to me that they will start with one or two and this may increase to up to six >>>>mm You ask: ps timbo, once again you appear somewhat over keen to downplay any positive speculation on SFX-01's near term prospects, why is that???... On the contrary, I am positive on the company's prospects. I think given the risk reward ratio they look very undervalued and I have a meaningful amount invested here, however, I believe that investors need to take a realistic view on prospects and timings. If investors have unrealistic expectations on timings (based on bulletin board speculation) then when those expectations are not met, it is likely to lead to investor disappointment, some of which will be misdirected at the company, rather than those responsible for inflating expectations. No one benefits from that, except (possibly) short term traders. I'm afraid that that an end of January completion date for a Data and Safety Monitoring Board review on the first 100 completed patients is totally inconsistant with what the company recently announced on December 10th, when they stated that data from the STAR COVID study could be potentially available in Q4 2021. If recruitment were occuring as quickly as you believe, then surely then the data from the completed trial would be available in Q3 or even Q2? So why wouldn't the company refer to that in the statement on Dec 10th? Investors would be best advised to base there investment decisions on verifiable statements from the company, not uninformed bulletin board speculation by anonymous avatars.
ADVFN Advertorial
Your Recent History
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211201 04:50:29